SecBot SecBot

INBX

Inhibrx Biosciences, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0002007919 Biotech & Drug Discovery
$88.61 −4.77 (−5.11%)
Oct 26 4:00 PM ET · prev $93.38
Market cap
$1.4B
Small cap
Consensus
Buy
80% Buy or better · 10 analysts
Median target
$245.00
+176% · range $230.00–325.00
Next earnings
Nov 13
in 18 days
1 year
+50.6%
from $58.85 · Oct 27
30 days
−12.9%
from $101.71
52-week range
$58.39–141.84
−38% from high · low Mar 27
Avg volume 20D
217.2K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$6.1M
3 buyers · 1 seller · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
18
analyzed by SecBot
SecBot read BULLISH 12 reports · 90 days
Balance 1 bearish · 7 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 8/12 ·Next Earnings date, Nov 13, 2026
Strongest BULLISH CEO Mark Lappe made a large open-market purchase cluster totaling ~$2.6M across six trades on September 8…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $6.3M at an average $101.52. 1 insider sold $279.0K. Price is 13% below their cost.

  • InstitutionsMIXED

    Q2 2026: 19 added (1 new), 15 trimmed or exited. Largest new: First Trust Advisors $12.2M.

  • AnalystsBULLISH

    8 of 10 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$12.2M
in new stakes
FundMoveSharesValue
BANK OF AMERICA CORP /DE/DOUBLED841,141$79.7M
Schonfeld Strategic Advisors LLCDOUBLED697,586$66.1M
GOLDMAN SACHS GROUP INCDOUBLED338,176$32.0M
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDADD271,700$25.7M
MILLENNIUM MANAGEMENT LLCTRIM147,200$13.9M
FIRST TRUST ADVISORS LPNEW128,424$12.2M
VANGUARD PORTFOLIO MANAGEMENT LLCADD122,557$11.6M
NORGES BANKTRIM90,300$8.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 80% rate it Buy or better
Strong Buy3Buy5Hold2Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +176%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 24, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy

Insider ledger

Form 4
$6.3M
bought · 3 insiders
$279.0K
sold · 1 insider
−12.7%
vs their $101.52 cost
DateInsiderTypeValue
Oct 14, 2026
Lappe Mark
Chief Executive Officer
BUY$207.7K
Oct 14, 2026
Lappe Mark
Chief Executive Officer
BUY$209.9K
Oct 14, 2026
Lappe Mark
Chief Executive Officer
BUY$8.6K
Oct 14, 2026
Lappe Mark
Chief Executive Officer
BUY$205.9K
Oct 14, 2026
Lappe Mark
Chief Executive Officer
BUY$208.3K
Sep 28, 2026
Lappe Mark
Chief Executive Officer
BUY$148.3K
Sep 28, 2026
Lappe Mark
Chief Executive Officer
BUY$305.1K
Sep 25, 2026
Lappe Mark
Chief Executive Officer
BUY$328.6K

Earnings setup

Estimates
Nov 13
reports in 18 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Sep 8, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
CEO Mark Lappe purchased $426K of INBX stock in three open-market transactions on October 14, 2026, at an average…
INSIDER-BUY — Impact 4/10
Oct 14, 2026 Insider
Lappe Mark bought 2,470 shares
Chief Executive Officer @ $84.07 ($207.7K)
Oct 14, 2026 Insider
Lappe Mark bought 2,470 shares
Chief Executive Officer @ $85.00 ($209.9K)
Oct 14, 2026 Insider
Lappe Mark bought 100 shares
Chief Executive Officer @ $85.76 ($8.6K)
Sep 28, 2026 SEC
Two INBX insiders — CEO Mark Lappe and Director Jon Faiz Kayyem — made open-market purchases totaling $829K over a…
CLUSTER — Impact 5/10
Sep 17, 2026 SEC
Inhibrx Biosciences (INBX) insider cluster shows a director (Kayyem) making a $500K open-market purchase at…
CLUSTER — Impact 5/10
Sep 8, 2026 Trading halt
Halt Resumed: INBX — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-08T11:25:00.000Z | Resumed 2026-09-08T12:00:00.000Z
Jun 30, 2026 Inst.
BANK OF AMERICA CORP — DOUBLED
841,141 shares ($79.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 13, 2026
Earnings date
INBX Q3 2026 Earnings Scheduled — 2026-11-13
Apr 14, 2027
FDA decision date
PDUFA: INBX — Ozekibart in unresectable or metastatic conventional chondrosarcoma — 2027-04-14
FDA target action date 2027-04-14 for INBX (Inhibrx Biosciences, Inc.). Drug: Ozekibart. Indication: unresectable or metastatic conventional…
Recent
Sep 8, 2026
Trading halt
Halt Resumed: INBX — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-08T11:25:00.000Z | Resumed 2026-09-08T12:00:00.000Z
Sep 8, 2026
Trading halt
Trading Halt: INBX — T1 (News Pending)
Inhibrx Biosciences | Market: NASDAQ | Code: T1 — News Pending
Sep 8, 2026
Trading halt
Trading Halt: INBX — T2 (News Released)
Inhibrx Biosciences | Market: NASDAQ | Code: T2 — News Released
Sep 8, 2026
Trading halt
Trading Halt: INBX — T3 (News and Resumption Times)
Inhibrx Biosciences | Market: NASDAQ | Code: T3 — News and Resumption Times
Sep 4, 2026
Company news
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq…

SecBot reports

18 filings · 11 bullish · 1 bearish · 6 neutral
All INBX filing & press-release reports (18)